Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism

British Journal of Pharmacology

Volumn 170, Issue 3, 2013, Pages 679-692

  Hill, T D M ^a   Cascio, M G ^b   Romano, B ^b   Duncan, M ^d   Pertwee, R G ^b,c   Williams, C M ^a   Whalley, B J ^a   Hill, A J ^a  

^a UNIVERSITY OF READING   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d Porton Down Science Park   (United Kingdom)

Author keywords

anticonvulsant; cannabidiol; cannabidivarin; cannabinoid; epilepsy; isobologram; radioligand binding assays; seizure; tolerability

Indexed keywords

CANNABIDIOL; CANNABIDIVARIN; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABIS; DELTA9 TETRAHYDROCANNABIVARIN; DRONABINOL; PENTETRAZOLE; PILOCARPINE; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; AUDIOGENIC SEIZURE; BINDING AFFINITY; CONTROLLED STUDY; CONVULSION; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; GRIP STRENGTH; IN VIVO STUDY; LIGAND BINDING; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE; TASK PERFORMANCE;

ANTICONVULSANT; CANNABIDIOL; CANNABIDIVARIN; CANNABINOID; EPILEPSY; ISOBOLOGRAM; RADIOLIGAND BINDING ASSAYS; SEIZURE; TOLERABILITY;

ANIMALS; ANTICONVULSANTS; BRAIN; CANNABIDIOL; CANNABINOIDS; CANNABIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HAND STRENGTH; MALE; MICE; MICE, INBRED DBA; MOTOR ACTIVITY; NOISE; PENTYLENETETRAZOLE; PHYTOTHERAPY; PILOCARPINE; PLANT EXTRACTS; PLANTS, MEDICINAL; PROTEIN BINDING; RATS; RATS, INBRED WKY; RECEPTOR, CANNABINOID, CB1; SEIZURES;

EID: 84884550462     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12321     Document Type: Article

References (57)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC). Br J Pharmacol 164: S1-S324.
2. BNF (2011). British National Formulary, 62nd edn. British Medical Association and Royal Pharmaceutical Society of Great Britain: London.
3. Cheng YC, Prusoff WH, (1973). Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
4. Chesher G, Jackson D, (1974). Anticonvulsant effects of cannabinoids in mice: drug interactions within cannabinoids and cannabinoid interactions with phenytoin. Psychopharmacology (Berl) 37: 255-264.
5. Coenen A, Drinkenburg W, Inoue M, Van Luijtelaar E, (1992). Genetic models of absence epilepsy, with emphasis on the WAG/Rij strain of rats. Epilepsy Res 12: 75-86.
6. Consroe P, Benedito MAC, Leite JR, Carlini EA, Mechoulam R, (1982). Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol 83: 293-298.
7. Corcoran ME, McCaughran JJA, Wada JA, (1973). Acute antiepileptic effects of Δ9-tetrahydrocannabinol in rats with kindled seizures. Exp Neurol 40: 471-483.
8. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, et al. (1980). Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21: 175-185.
9. De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, et al. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163: 1479-1494.
10. Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, Fleming S, et al. (2012). Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ 9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl) 219: 859-873.
11. Elsohly MA, Slade D, (2005). Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 78: 539-548.
12. Essman WB, Sudak FN, (1964). Audiogenic seizure in genetically susceptible mice: relation of hypothermia to onset and susceptibility. Exp Neurol 9: 228-235.
13. Farrimond JA, Hill AJ, Jones NA, Stephens GJ, Whalley BJ, Williams CM, (2009). A cost-effective high-throughput digital system for observation and acquisition of animal behavioral data. Behav Res Methods 41: 446-451.
14. FDA (2004). Guidance for industry: botanical drug products [Online]. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070491.pdf (accessed 13 August 2013).
15. Formukong EA, Evans AT, Evans FJ, (1988). Inhibition of the cataleptic effect of tetrahydrocannabinol by other constituents of Cannabis sativa L. J Pharm Pharmacol 40: 132-134.
16. Fried P, McIntyre D, (1973). Electrical and behavioral attenuation of the anti-convulsant properties of 9-THC following chronic administrations. Psychopharmacology (Berl) 31: 215-227.
17. Hermann BP, Seidenberg M, Bell B, Woodard A, Rutecki P, Sheth R, (2000). Comorbid psychiatric symptoms in temporal lobe epilepsy: association with chronicity of epilepsy and impact on quality of life. Epilepsy Behav 1: 184-190.
18. Hill A, Mercier M, Hill T, Glyn S, Jones N, Yamasaki Y, et al. (2012a). Cannabidivarin is anticonvulsant in mouse and rat in vitro and in seizure models. Br J Pharmacol 167: 1629-1642.
19. 9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia 51: 1522-1532.
20. Hill AJ, Williams CM, Whalley BJ, Stephens GJ, (2012b). Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther 133: 79-97.
21. Hitiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ, (2007). Predictors of pharmacoresistant epilepsy. Epilepsy Res 75: 192-196.
22. Hosford DA, Wang Y, (1997). Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia 38: 408-414.
23. 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacol Biochem Behav 73: 911-919.
24. Jensen LH, Petersen EN, Braestrup C, (1983). Audiogenic seizures in DBA/2 mice discriminate sensitively between low efficacy benzodazepine receptor agonists and inverse agonists. Life Sci 33: 393-399.
25. Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, Whalley BJ, et al. (2010). Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther 332: 569-577.
26. Jones NA, Glyn SE, Akiyama S, Hill TDM, Hill AJ, Weston SE, et al. (2012). Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 21: 344-352.
27. Kanner AM, Schachter SC, Barry JJ, Hersdorffer DC, Mula M, Trimble M, et al. (2012). Depression and epilepsy: epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence. Epilepsy Behav 24: 156-168.
28. Karler R, Turkanis SA, (1980). Subacute cannabinoid treatment: anticonvulsant activity and withdrawal excitability in mice. Br J Pharmacol 68: 479-484.
29. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
30. Leonardi M, Ustun TB, (2002). The global burden of epilepsy. Epilepsia 43: 21-25.
31. Löscher W, (2011). Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 20: 359-368.
32. Marescaux C, Vergnes M, (1995). Genetic absence epilepsy in rats from Strasbourg (GAERS). Ital J Neurol Sci 16: 113-118.
33. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
34. McPartland JM, Russo EB, (2001). Cannabis and cannabis extracts. J Cannabis Ther 1: 103-132.
35. Nevins ME, Nash SA, Beardsley PM, (1993). Quantitative grip strength assessment as a means of evaluating muscle relaxation in mice. Psychopharmacology (Berl) 110: 92-96.
36. Ortinski P, Meador KJ, (2004). Cognitive side effects of antiepileptic drugs. Epilepsy Behav 5: 60-65.
37. Pertwee R, (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br J Pharmacol 153: 199-215.
38. 1 receptors. Life Sci 76: 1307-1324.
39. Perucca E, Beghi E, Dulac O, Shorvon S, Tomson T, (2000). Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res 41: 107-139.
40. Ross HR, Napier I, Connor M, (2008). Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol. J Biol Chem 283: 16124-16134.
41. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, et al. (1999). Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 126: 665-672.
42. Russo E, Guy GW, (2006). A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66: 234-246.
43. Russo EB, (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163: 1344-1364.
44. Russo EB, Burnett A, Hall B, Parker KK, (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30: 1037-1043.
45. Ryan D, Drysdale AJ, Pertwee RG, Platt B, (2006). Differential effects of cannabis extracts and pure plant cannabinoids on hippocampal neurones and glia. Neurosci Lett 408: 236-241.
46. Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J, (2011). Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. J Neurosci Res 89: 1509-1518.
47. Schachter SC, (2007). Currently available antiepileptic drugs. Neurother 4: 4-11.
48. Scutt A, Williamson EM, (2007). Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcif Tissue Int 80: 50-59.
49. Sed J, Urdzíková L, Jendelová P, Syková E, (2008). Methods for behavioral testing of spinal cord injured rats. Neurosci Biobehav Rev 32: 550-580.
50. Tallarida RJ, (2006). An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther 319: 1-7.
51. Thomas A, Ross R, Saha B, Mahadevan A, Razdan R, Pertwee RG, (2004). 6″-azidohex-2″-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. Eur J Pharmacol 487: 213-221.
52. Tõth A, Boczán J, Kedei N, Lizanecz E, Bagi Z, Papp Z, et al. (2005). Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. Brain Res Mol Brain Res 135: 162-168.
53. Valdeolivas S, Satta V, Pertwee RG, Ferna'ndez-Ruiz J, Sagredo O, (2012). Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors. ACS Chem Neurosci 3: 400-406.
54. Wallace MJ, Wiley JL, Martin BR, DeLorenzo RJ, (2001). Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol 428: 51-57.
55. Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ, (2003). The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther 307: 129-137.
56. Whalley BJ, Wilkinson JD, Williamson EM, Constanti A, (2004). A novel component of cannabis extract potentiates excitatory synaptic transmission in rat olfactory cortex in vitro. Neurosci Lett 365: 58-63.
57. Wilkinson JD, Whalley BJ, Baker D, Pryce G, Constanti A, Gibbons S, et al. (2003). Medicinal cannabis: is 9-tetrahydrocannabinol necessary for all its effects? J Pharm Pharmacol 55: 1687-1694.